RAMM Pharma Corp. (CSE:RAMM)
Canada
· Delayed Price · Currency is CAD 0.0150
0.00 (0.00%)
Apr 20, 2026, 9:04 AM EST
RAMM Pharma Income Statement
Financials in millions CAD. Fiscal year is November - October.
Millions CAD. Fiscal year is Nov - Oct.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jan '26 Jan 31, 2026 | Oct '25 Oct 31, 2025 | Oct '24 Oct 31, 2024 | Oct '23 Oct 31, 2023 | Oct '22 Oct 31, 2022 | Oct '21 Oct 31, 2021 | 2020 - 2018 |
| Revenue | 2.56 | 3.36 | 4.34 | 5.07 | 3.9 | 4.12 | Upgrade
|
| Revenue Growth (YoY) | -41.70% | -22.60% | -14.28% | 29.97% | -5.31% | -24.40% | Upgrade
|
| Cost of Revenue | 1.8 | 2.51 | 2.57 | 4.64 | 3.41 | 4.15 | Upgrade
|
| Gross Profit | 0.76 | 0.85 | 1.78 | 0.42 | 0.48 | -0.04 | Upgrade
|
| Selling, General & Admin | 4.93 | 5.3 | 8.42 | 7.36 | 8.42 | 6.6 | Upgrade
|
| Other Operating Expenses | 0.08 | 0.08 | 0.12 | 0.15 | - | - | Upgrade
|
| Operating Expenses | 5.01 | 5.38 | 10.72 | 7.51 | 8.42 | 6.6 | Upgrade
|
| Operating Income | -4.25 | -4.53 | -8.94 | -7.09 | -7.94 | -6.64 | Upgrade
|
| Interest Expense | -0.24 | -0.24 | -0.04 | -0.05 | -0.01 | -0.01 | Upgrade
|
| Interest & Investment Income | 0.01 | 0.01 | 0.03 | 0.2 | 0.16 | 0.37 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | - | -0.71 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.15 | -0.07 | -0 | -0.04 | 0.08 | -0.3 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.13 | -0.05 | 0.02 | 0.35 | 0.17 | 0.03 | Upgrade
|
| EBT Excluding Unusual Items | -4.75 | -4.89 | -8.93 | -6.64 | -7.54 | -7.26 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -12.93 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | -0.23 | 0.27 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.98 | 0.77 | - | - | - | - | Upgrade
|
| Asset Writedown | -4.77 | -4.77 | -7.56 | -1.07 | -0.25 | - | Upgrade
|
| Other Unusual Items | - | - | - | - | - | -0.11 | Upgrade
|
| Pretax Income | -8.54 | -8.89 | -16.49 | -7.71 | -20.95 | -7.1 | Upgrade
|
| Income Tax Expense | 0.1 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Net Income | -8.65 | -8.91 | -16.5 | -7.72 | -20.96 | -7.11 | Upgrade
|
| Net Income to Common | -8.65 | -8.91 | -16.5 | -7.72 | -20.96 | -7.11 | Upgrade
|
| Shares Outstanding (Basic) | 119 | 119 | 119 | 121 | 123 | 108 | Upgrade
|
| Shares Outstanding (Diluted) | 119 | 119 | 119 | 121 | 123 | 108 | Upgrade
|
| Shares Change (YoY) | - | - | -1.36% | -1.42% | 13.20% | 7.85% | Upgrade
|
| EPS (Basic) | -0.07 | -0.07 | -0.14 | -0.06 | -0.17 | -0.07 | Upgrade
|
| EPS (Diluted) | -0.07 | -0.07 | -0.14 | -0.06 | -0.17 | -0.07 | Upgrade
|
| Free Cash Flow | -1.11 | -1.06 | -4.05 | -4.4 | -6.08 | -4.26 | Upgrade
|
| Free Cash Flow Per Share | -0.01 | -0.01 | -0.03 | -0.04 | -0.05 | -0.04 | Upgrade
|
| Gross Margin | 29.71% | 25.25% | 40.92% | 8.34% | 12.43% | -0.91% | Upgrade
|
| Operating Margin | -165.68% | -134.83% | -205.86% | -139.90% | -203.64% | -161.37% | Upgrade
|
| Profit Margin | -337.31% | -265.13% | -380.06% | -152.43% | -537.79% | -172.66% | Upgrade
|
| Free Cash Flow Margin | -43.32% | -31.54% | -93.17% | -86.87% | -156.02% | -103.52% | Upgrade
|
| EBITDA | -3.78 | -3.93 | -7.97 | -6.03 | -7 | -6.01 | Upgrade
|
| EBITDA Margin | -147.53% | -116.92% | -183.49% | -119.00% | -179.69% | -145.94% | Upgrade
|
| D&A For EBITDA | 0.47 | 0.6 | 0.97 | 1.06 | 0.93 | 0.63 | Upgrade
|
| EBIT | -4.25 | -4.53 | -8.94 | -7.09 | -7.94 | -6.64 | Upgrade
|
| EBIT Margin | -165.68% | -134.83% | -205.86% | -139.90% | -203.64% | -161.37% | Upgrade
|
| Advertising Expenses | - | 0.02 | 0.06 | 0.2 | 0.42 | 0.09 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.